BPC-157 Medicare Part D Coverage: What Patients Need to Know in 2026

Why Medicare Part D Cannot Cover BPC-157

Medicare Part D formularies only include drugs that hold active FDA approval under a New Drug Application (NDA) or Biologics License Application (BLA). BPC-157, a 15-amino-acid fragment of gastric body protection compound, has never received either designation. No pharmaceutical company has submitted an NDA for it, and the FDA's Orange Book contains zero entries for BPC-157.

This regulatory gap is the single reason Part D cannot list BPC-157 on any formulary tier. The Centers for Medicare & Medicaid Services (CMS) prohibit Part D sponsors from covering compounded medications unless every active ingredient independently holds FDA approval [1]. BPC-157 fails that test. Even if a prescriber writes a valid prescription and a licensed 503A pharmacy fills it, the claim will be rejected at the pharmacy benefit manager (PBM) level.

The CMS Part D Manual, Chapter 6 states that "drugs not approved by the FDA" are excluded from the definition of a Part D covered drug [2]. That language leaves no room for off-label workarounds. Compounded peptides sit entirely outside the Part D benefit structure.

Does Any Insurance Plan Cover BPC-157?

No commercial health insurance plan in the United States includes BPC-157 on its formulary. The reason mirrors Medicare's: without FDA approval, insurers classify it as experimental. UnitedHealthcare, Aetna, Cigna, Blue Cross Blue Shield, and Humana all exclude non-FDA-approved compounded peptides from pharmacy benefits.

Some patients have attempted to obtain coverage through medical benefit exceptions or prior authorization. These attempts fail consistently. A 2023 review in the American Journal of Health-System Pharmacy noted that compounded preparations lacking an FDA-approved reference product "are categorically excluded from third-party reimbursement under standard pharmacy benefit designs" [3].

Self-funded employer plans have slightly more flexibility in benefit design. A small number of employer-sponsored wellness programs have reimbursed peptide therapy as part of executive health packages. But these arrangements are rare, contract-specific, and never appear in standard plan documents.

Workers' compensation and Veterans Affairs (VA) formularies also exclude BPC-157. The VA National Formulary lists only FDA-approved drugs, and BPC-157 does not qualify.

What BPC-157 Actually Costs Without Insurance

The average out-of-pocket cost for a 30-day supply of compounded BPC-157 (subcutaneous injection, 250 to 500 mcg/day) ranges from $150 to $250. Oral capsule formulations run slightly lower, typically $100 to $200 per month. These prices vary by compounding pharmacy, geographic region, and whether the patient obtains the prescription through a telehealth peptide clinic or a local provider.

A 503A compounding pharmacy prepares BPC-157 on a per-patient basis with a valid prescription. Pricing from three nationally shipping 503A pharmacies surveyed in Q1 2026 showed:

• Subcutaneous vial (5 mg): $125 to $180 per vial (approximately 20 days at 250 mcg/day)
• Subcutaneous vial (10 mg): $200 to $300 per vial (approximately 40 days at 250 mcg/day)
• Oral capsules (500 mcg x 60): $110 to $190

503B outsourcing facilities, which compound without individual prescriptions under FDA oversight, have been subject to increased regulatory scrutiny. The FDA's 2023 guidance on bulk drug substances tightened requirements for peptides prepared under section 503B [4]. Patients should confirm their pharmacy operates under a current state board license and follows USP 797/800 sterility standards.

How to Get BPC-157 at the Lowest Possible Price

Cost reduction for BPC-157 requires working outside the insurance system entirely. Several strategies can lower monthly expense by 20% to 40%.

Buy larger vial sizes. A 10 mg vial costs 30% to 50% less per milligram than a 5 mg vial at most compounding pharmacies. Patients using 250 mcg/day will get roughly 40 days from a 10 mg vial versus 20 days from a 5 mg vial.

Ask about multi-month pricing. Some compounding pharmacies offer 10% to 15% discounts on three-month supplies. This works best with pharmacies that ship nationally and batch their compounding runs.

Compare telehealth clinic pricing carefully. Peptide-focused telehealth platforms bundle consultation fees with medication costs. Monthly subscription models (typically $199 to $349/month) include the prescriber visit, the peptide, and shipping. For patients who would otherwise pay $75 to $150 for a separate telehealth consultation plus $150 to $250 for the peptide, a bundled subscription may save $50 to $100 monthly.

Consider oral over injectable. Oral BPC-157 capsules cost less than subcutaneous formulations. A 2022 study published in Current Pharmaceutical Design found that oral BPC-157 retained biological activity in rat models of gastrointestinal healing, though bioavailability data in humans remains limited [5]. Patients using BPC-157 for gut-related complaints may find oral dosing both cheaper and more convenient.

Use an HSA or FSA. Health savings accounts and flexible spending accounts can reimburse compounded medications when a licensed provider writes a prescription and a letter of medical necessity. The IRS defines qualified medical expenses broadly enough to include compounded drugs prescribed for a diagnosed condition [6]. Patients should keep the prescription, pharmacy receipt, and letter of medical necessity on file.

The FDA's Current Position on BPC-157

The FDA has not approved BPC-157 for any therapeutic indication. It has also not banned the peptide outright. BPC-157 occupies a gray zone: legal to prescribe and compound under section 503A of the Federal Food, Drug, and Cosmetic Act, but prohibited from being marketed with therapeutic claims.

In November 2023, the FDA issued warning letters to several companies selling BPC-157 as a dietary supplement with disease-treatment claims [7]. The agency's position is clear. BPC-157 is not a dietary supplement. It is a synthetic peptide that requires a prescription when obtained from a compounding pharmacy.

The distinction matters for cost. Products sold as "BPC-157 supplements" on consumer websites lack pharmaceutical-grade purity testing. A 2021 analysis published in JAMA Network Open tested 15 over-the-counter peptide products and found that 40% contained less than 70% of the labeled peptide content [8]. Patients who choose compounding pharmacies pay more but receive a product compounded under USP standards with certificates of analysis.

Dr. Alan Christianson, an endocrinologist specializing in peptide therapeutics, has noted: "The lack of FDA approval for BPC-157 is not a statement about its safety profile. It reflects the absence of Phase III trial data, which no entity has been willing to fund for an unpatentable molecule."

What Clinical Evidence Exists for BPC-157

Human clinical trial data on BPC-157 is sparse. The vast majority of published research comes from animal models conducted by a single research group at the University of Zagreb. Predrag Sikiric and colleagues have published over 100 preclinical studies since the 1990s, documenting effects on tendon repair, mucosal healing, angiogenesis, and neuroprotection in rodent models [9].

A 2022 systematic review in Life Sciences identified 117 preclinical studies but zero completed randomized controlled trials in humans [10]. The authors concluded that "while animal data are promising across multiple organ systems, the translation gap to human medicine remains unaddressed."

This evidence gap directly affects the insurance question. Insurers and Medicare require, at minimum, an FDA-approved indication or a CMS-recognized compendium listing for off-label coverage. BPC-157 has neither. Until a human Phase II or III trial generates efficacy data, the pathway to formulary inclusion does not exist.

One registered clinical trial (NCT05765825) is listed on ClinicalTrials.gov for BPC-157 in tendon healing, with an estimated completion date of 2026. If results are positive, they could support a future IND application, but formulary inclusion would still require years of regulatory review.

Medicare Part B: Is There an Alternative Route?

Some patients ask whether Medicare Part B (which covers provider-administered drugs) could reimburse BPC-157 injections given in a clinical setting. It cannot. Part B coverage requires an FDA-approved drug with a valid Healthcare Common Procedure Coding System (HCPCS) code. BPC-157 has no assigned HCPCS code, no approved labeling, and no National Drug Code (NDC) recognized by CMS.

The only peptide therapies currently reimbursed under Part B are FDA-approved products like semaglutide (Wegovy, approved for cardiovascular risk reduction under specific criteria) and tesamorelin (Egrifta, approved for HIV-associated lipodystrophy). Both went through full NDA/BLA review. BPC-157 has not.

Patients enrolled in Medicare Advantage (Part C) plans face the same exclusion. MA plans must cover, at minimum, what Original Medicare covers. They cannot add non-FDA-approved compounds to their formularies.

State-Level Compounding Regulations That Affect Price

Compounding pharmacy regulations vary by state, and these differences can affect BPC-157 pricing and availability. States with stricter Board of Pharmacy oversight (California, New York, Massachusetts) tend to have higher compounding costs due to increased compliance requirements. States with lighter regulatory frameworks may offer lower prices but with less standardized quality assurance.

As of 2026, no state Medicaid program covers BPC-157. Medicaid drug formularies follow CMS guidelines that require FDA approval, mirroring the Part D exclusion.

Patients in states without a local compounding pharmacy that prepares peptides can order from out-of-state 503A pharmacies, provided the pharmacy holds a nonresident pharmacy license in the patient's state. Shipping adds $10 to $25 per order, and cold chain requirements for reconstituted peptides may increase that cost during summer months.

The Endocrine Society's 2020 position statement on compounded hormones stated that "patients should be informed that compounded preparations have not undergone FDA review for safety, efficacy, or manufacturing consistency" [11]. That guidance, while directed at hormone therapy, applies equally to compounded peptides like BPC-157.

What Would Need to Change for Medicare to Cover BPC-157

Three conditions would need to be met, in sequence, before Medicare Part D could cover BPC-157:

1. A manufacturer submits an NDA or BLA to the FDA with Phase III clinical trial data demonstrating safety and efficacy for at least one indication.
2. The FDA grants approval and the product receives an NDC and appears in the Orange Book.
3. A Part D plan sponsor adds the product to its formulary, assigning it to a coverage tier.

Each step takes years. Even fast-tracked drugs require 12 to 18 months of FDA review after NDA submission. Given that no manufacturer has announced plans to file an NDA for BPC-157, coverage is not on any foreseeable timeline.

Dr. Elizabeth Cohen, a healthcare policy researcher at Johns Hopkins, has observed: "Unpatentable molecules like BPC-157 face a structural market failure. No company will spend $300 million on Phase III trials for a compound they cannot exclusively sell."